KNSA — Kiniksa Pharmaceuticals International, plc stock price, charts and financials

QT80Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
73.41
-0.93-1.25%
OverviewShort InterestFilings
KNSAQT80Kiniksa Pharmaceuticals International, plc·NASDAQ
73.41-1.25%
News
Down 1.3% — KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LQDA-0.31%$83.85CORT-1.48%$112.80TRLV-0.58%$8.60RPRX-2.16%$57.17SYRE-3.46%$94.93ATR+2.10%$136.77PRAX-0.75%$305.51IONS+5.25%$54.49
Snapshot
Index-P/E69.48EPS (ttm)1.07Insider Own5.95%Shs Outstand76.21MPerf Week18.30%
Market Cap5.67BForward P/E36.18EPS next Y2.05Insider Trans-16.70%Shs Float72.86MPerf Month18.21%
Enterprise Value5.50BPEG0.04EPS next Q-Inst Own-Short Float6.19%Perf Quarter38.23%
Income79.31MP/S6.74EPS this Y53.13%Inst Trans-Short Ratio5.53Perf Half Y69.11%
Sales840.85MP/B8.82EPS next Y47.43%ROA9.00%Short Interest4.51MPerf YTD80.22%
Book/sh-P/C31.14EPS next 5Y45.59%ROE13.65%52W High81.90 -10.37%Perf Year147.31%
Cash/sh-P/FCF30.94EPS past 3/5Y-33.93% -ROIC9.71%52W Low29.53 148.63%Perf 3Y268.02%
Dividend Est.-EV/EBITDA49.05Sales past 3/5Y45.52% -Gross Margin54.49%Volatility8.42% 5.11%Perf 5Y412.69%
Dividend TTM-EV/Sales6.54EPS Y/Y TTM251.67%Oper. Margin11.92%ATR (14)3.69Perf 10Y-
Dividend Ex-Date-Quick Ratio3.49Sales Y/Y TTM78.25%Profit Margin9.59%RSI (14)64.24Recom2.00
Dividend Gr. 3/5Y-Current Ratio3.90EPS Q/Q145.45%SMA2012.28%Beta0.06Target Price86.40
Payout0.00%Debt/Eq0.01Sales Q/Q55.07%SMA5026.42%Rel Volume1.33Prev Close74.34
Employees366LT Debt/Eq0.01EarningsOct 27SMA20054.95%Avg Volume775.91KPrice73.41
IPO DateMay 24, 2018Option/ShortYes / YesEPS/Sales Surpr.33.79% 3.96%Net Debt/EBITDA-1.49Volume1,034,262Change-1.25%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedGoldman SachsBuy$75 → $90
Jul-29-26ReiteratedWedbushOutperform$72 → $99
Jul-29-26ReiteratedCanaccord GenuityBuy$62 → $98
Jul-23-26ReiteratedGoldman SachsBuy$55 → $75
Jul-13-26ReiteratedWells FargoOverweight$34 → $74
Jun-29-26ReiteratedWedbushOutperform$59 → $72
Apr-29-26ReiteratedWedbushOutperform$58 → $59
Apr-28-26ReiteratedJefferiesBuy$54 → $71
Apr-16-26ReiteratedWedbushOutperform$50 → $58
Feb-19-26InitiatedCanaccordBuy$62
Latest News
Today
Today11:01AM
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlookzacks.com
Jul-30-26
Jul-30-2601:21PM
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?zacks.com
Jul-28-26
Jul-28-2602:30PM
Which stocks are gapping on Tuesday?ChartMill
10:23AM
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:05AM
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlightsmarketbeat.com
09:50AM
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimateszacks.com
07:30AM
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Executionglobenewswire.com
Jul-23-26
Jul-23-2609:25AM
5 Stocks With Recent Price Strength Despite Recent Market Volatilityzacks.com
Jul-22-26
Jul-22-2609:56AM
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Whyzacks.com
Jul-21-26
Jul-21-2610:50AM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings MomentumChartMill
Jul-15-26
Jul-15-2611:08AM
Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent GainsSeekingAlpha
Jul-14-26
Jul-14-2610:20AM
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gainszacks.com
Jul-13-26
Jul-13-2608:05AM
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74Benzinga
Jul-06-26
Jul-06-2609:56AM
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Whyzacks.com
Jun-30-26
Jun-30-2601:01PM
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?zacks.com
Company

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue84167842327022039000
Cost of Goods Sold Incl. D&A3833076157239430
Gross Profit45837036221419729-4-30
Selling, General and Administrative Excl. Other2311961681299886443422
Research and Development1279711276659911013387
Other Operating Expense001283425100-1
Operating Income10077-46-2510-157-157-170-108
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)14129910165
Net Income Before Taxes11489-36-1711-157-156-164-103
Income Taxes34307-31-17215-20
Consolidated Net Income8059-4314183-158-161-162-103
Net Income From Continuing Operations8059-4314183-158-161-162-103
Net Income8059-4314183-158-161-162-103
EPS (Recurring)1.070.80-0.600.202.64-2.30-2.61-2.99-3.49
EPS (Basic, Before Extraordinaries)1.070.80-0.600.202.64-2.30-2.61-2.99-3.49
EPS (Diluted)0.980.75-0.600.202.60-2.30-2.61-2.99-3.49
EBITDA11390-34-1413-154-152-161-108
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio74.9155.00—87.705.76————
Price To Sales Ratio6.814.503.324.554.7020.82———
Gross Margin54.4654.5785.5879.2689.5574.36———
Operating Margin11.8911.36-10.87-9.264.55-402.56———
Net Margin9.518.70-10.175.1983.18-405.13———
Shares Outstanding787471706969625430
Market Capitalization5,7263,0531,4041,2281,0348121,096597843
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$89.17$71.30$53.44$35.57$17.70● Close Price0.00M6.77M13.53M20.30M27.07MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cole G BradleyDirectorJul 29 '26Sale81.433,673299,09211,672Jul 31
Malley ThomasDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Levy Richard SDirectorMay 29 '26Option Exercise0.002,799021,956Jun 02
Cole G BradleyDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Quart Barry DDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Popovits Kimberly JDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
McCain Tracey LDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Paolini John F.CHIEF MEDICAL OFFICERMay 01 '26Option Exercise10.3658,424605,273124,047May 05
Paolini John F.CHIEF MEDICAL OFFICERMay 01 '26Sale53.7158,4243,137,82365,623May 05
Patel Sanj KCHAIRMAN & CEOMay 01 '26Option Exercise30.9348,5651,502,11548,565May 01
Patel Sanj KCHAIRMAN & CEOMay 01 '26Sale54.0248,5652,623,4810May 01
Patel Sanj KCHAIRMAN & CEOApr 30 '26Option Exercise30.932,14166,2212,141Apr 30
Patel Sanj KCHAIRMAN & CEOApr 30 '26Sale54.012,141115,6350Apr 30
Patel Sanj KCHAIRMAN & CEOApr 29 '26Option Exercise30.9322,544697,28622,544Apr 30
Patel Sanj KCHAIRMAN & CEOApr 28 '26Sale51.86483,65425,081,9910Apr 30
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.